[Possibility of potentiating the antineoplastic effect of a folic acid antagonist by methylcobalamin analogs].
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D004359:Drug Therapy, Combination; D005260:Female; D005493:Folic Acid Antagonists / Q000008:administration & dosage*; D006824:Hybridization, Genetic; D007414:Intestinal Neoplasms / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011806:Quinolinium Compounds / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014805:Vitamin B 12 / Q000008:administration & dosage / Q000031:analogs & derivatives*
D005493:Folic Acid Antagonists; D011806:Quinolinium Compounds; C019476:mecobalamin; D014805:Vitamin B 12; D008727:Methotrexate
Vozmozhnost' usileniia protivoopukholevogogo deĭstviia antagonista folievoĭ kisloty analogami metilkobalamina.